Compare Novo Nordisk A/S (NVO) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs ABRDN Physical Gold Shares ETF — how do they compare? Novo Nordisk A/S trades at $38.47 (market cap $165.31B), while ABRDN Physical Gold Shares ETF trades at $39.96 (market cap $7.03B). The key difference: Novo Nordisk A/S is far larger — about 23.5× ABRDN Physical Gold Shares ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and ABRDN Physical Gold Shares ETF for 57 Days on average.
| NVO | SGOL | |
|---|---|---|
Market Cap | $165.31B | $7.03B |
Volume | 11,432,838 | 2,350,550 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $63.98 | $51.41 |
52-Week Low | $35.29 | $37.54 |
Typical Hold Time | 116 Days | 57 Days |
Enterprise Value | $179.56B | — |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
SGOL trades at $39.94, up 2.36% with a bearish technical outlook showing 17 sell signals versus 2 buy signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate uncertainty, though recent softer inflation data provided some support. Moving averages indicate strong bearish momentum while oscillators remain neutral, suggesting potential consolidation near current levels.
The outlook remains cautious with technical indicators favoring downside momentum, though oversold conditions could provide near-term support. Key risks include persistent inflation concerns and Fed policy uncertainty, while potential catalysts include geopolitical tensions and sustained gold demand from China. Investors should monitor Treasury yield movements and inflation data for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
